What is MindMaze?
Founded in 2012, MindMaze operates at the cutting edge of brain technology, developing sophisticated medical-grade virtual reality products designed to stimulate neural recovery. By integrating computer graphics, brain imaging, and neuroscience, the company has built a proprietary platform that facilitates intuitive human-machine interfaces. This unique technological stack allows for highly personalized therapeutic interventions, addressing critical needs in neuro-rehabilitation. With its headquarters in Switzerland, MindMaze has established itself as a global authority, bridging the gap between clinical research and scalable digital health solutions. The company's market position is defined by its commitment to evidence-based innovation, which has garnered interest from both healthcare-focused private equity firms and specialized credit managers.
How much funding has MindMaze raised?
MindMaze has raised a total of $338.5M across 4 funding rounds:
Angel/Seed
$8.5M
Private Equity
$100M
Unspecified
$125M
Other Financing Round
$105M
Angel/Seed (2015): $8.5M, investors not publicly disclosed
Private Equity (2016): $100M led by Hinduja Group
Unspecified (2021): $125M supported by AlbaCore Capital
Other Financing Round (2022): $105M featuring Hambro Perks, Concord Health Partners, and AlbaCore Capital
Key Investors in MindMaze
AlbaCore Capital
AlbaCore Capital Group is a prominent European credit manager specializing in private credit and special situations investments, providing capital solutions for mid-to-large cap companies.
Hambro Perks
Hambro Perks is an investment firm that partners with founders to build and scale technology-enabled businesses across various growth stages.
Concord Health Partners
Concord Health Partners focuses on strategic investments and business combinations within the healthcare sector, targeting companies with significant growth potential.
What's next for MindMaze?
With the recent influx of capital, MindMaze is poised to transition from its current development phase into a period of aggressive commercial expansion and clinical integration. The strategic focus will likely center on expanding the reach of its neuro-rehabilitation platforms into new international markets and enhancing the efficacy of its human-machine interface software. As the company continues to refine its medical-grade VR offerings, it is expected to prioritize regulatory milestones and clinical validation studies to ensure widespread adoption within hospital systems and rehabilitation centers. By leveraging its strong investor base, MindMaze is well-positioned to navigate the complexities of the digital health landscape, ultimately aiming to set a new standard for patient outcomes in neurological care.
See full MindMaze company page
